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Dabigatran is a direct thrombin inhibitor used as an alternative to warfarin for long term anticoagulation. Warfarin-related
nephropathy is an increasingly recognized entity, but recent evidence suggests that dabigatran can cause a WRN-like syndrome.
We describe a case of a biopsy-proven anticoagulant nephropathy related to dabigatran in a patient with IgA nephropathy and
propose that, despite the base glomerular disease, acute kidney injury was due to tubular obstruction by red blood cells and heme-
associated tubular injury, and through a mechanism involving inhibition of anticoagulation cascade and barrier abnormalities
caused by molecular mechanisms.
1. Introduction
Anticoagulant therapy plays a central role in the prevention
and treatment of venous and arterial thromboembolic dis-
eases. Recently, several oral anticoagulants were approved,
including the direct thrombin inhibitors such as dabigatran.
It has a quick onset of action, results in a predictable antico-
agulation response, and does not require routine laboratory
monitoring. However, concerns have been raised since there
is no antidote for treatment of secondary hemorrhages. We
report a case of a 69-year-old woman with a biopsy-proven
anticoagulant nephropathy related to dabigatran and discuss
the diagnostic and management approach.
2. Case Presentation
A 69-year-old white female with a past history of hyper-
tension presented with nausea, vomiting, and oliguria. The
patient had been in her usual state of health until 2 weeks
earlier, when she developed palpitations that prompted
her to seek medical care. New-onset atrial fibrillation was
diagnosed. After reversing into sinus rhythm with amio-
darone, she was discharged with a prescription of dabigatran
110mg twice daily (Pradaxa Boehringer). At this time serum
creatinine was 1,5mg/dL (corresponding to an estimated
glomerular filtration rate [eGFR] of 35,2mL/min/1,73m2
as calculated by the CKD-EPI [Chronic Kidney Disease
Epidemiology Collaboration] equation). Two weeks later she
started vomiting and having oliguria and was sent to our
medical facilities. She denied additional complaints and was
on dabigatran 100mg twice a day during the previous two
weeks.
The patient’s medical history included arterial hyperten-
sion medicated with ramipril. On admission blood pres-
sure was 212/98mmHg, pulse rate was 98 heart beats per
minute, and she was oliguric. The physical examination
revealed hydratedmucosa with no respiratory distress, crack-
les in bilateral lung fields, and mild lower-extremity edema.
Laboratory results showed the following: serum urea was
230mg/dL, serum creatinine was 8mg/dL, hemoglobin was
9.1 g/dL, white blood cell count was 14.7 × 103/𝜇L with
86% of PMN and 0.2% of eosinophils, platelet count was
369 × 103/𝜇L, prothrombin time (PT) was 25.3 seconds
with international normalized ratio (INR) of 2.3, activated
partial thromboplastin time (aPTT) was 68 seconds, LDH
was 531 IU/L, and C-reactive protein was 7.1mg/dL. A ran-
dom urine specimen revealed that leukocytes were 500/𝜇L,
proteinswere 100mg/dL, and hemoglobinwas 1mg/dL.Urine
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Figure 1: Prominent interstitial hemorrhage and intratubular casts
(haematoxylin/eosin staining, magnification 100x).
sediment had hematuria (>100 red blood cells (RBC)/high-
power field) and leukocyturia (6 leukocytes/high-power
field) without dysmorphic red blood cells or red blood
casts. Renal ultrasound suggested globular kidneys with reg-
ular shape but hyperechogenic cortical parenchyma without
hydronephrosis. The patient was then transferred to the
Nephrology Department. Due to oliguric acute renal failure
she started hemodialysis two days after being admitted and
proceeding with investigation. A peripheral blood smear did
not show schizocytes. C3 complement level was decreased
(52mg/dL). C4 and antistreptolysin were normal. Screening
for antinuclear antibody, antineutrophil cytoplasmic anti-
body, anti-glomerular basement membrane antibody, cryo-
globulins, and antiphospholipid antibody and VDRL test
were negative. After an inconclusive Doppler renal ultra-
sound, a contrast enhanced computed tomography angiogra-
phy was performed four days after admission and showed no
abnormalities. A transthoracic echocardiogramwas done and
illustrated normal sized left chambers without intracardiac
thrombus. After 3 sessions of hemodialysis a normal aPTT
was accomplished and due to persistent oliguria a biopsy was
performed.
Five glomeruli appeared normal. The tubulointerstitium
had large intratubular RBC casts, extensive tubular necrosis,
and interstitial hemorrhage (Figures 1 and 2). By immunoflu-
orescence thereweremesangial deposits of IgA (++), C3 (++),
K, and 𝜆 chains on 3 glomeruli (Figure 3).
So the diagnosis of IgA nephropathy, anticoagulant
nephropathy with acute tubular necrosis, and intersti-
tial hemorrhage was made. Following the kidney biopsy
there were perirenal haematoma and hypotension. Three
units of RBC were provided and resolution was achieved
under tight follow-up. After intravenous fluid reposition
she restored diuresis (hematuria). Two weeks later, renal
function improved, urine cleared, andpatientwas discharged.
Creatinine was 1.9mg/dL in the last clinical evaluation.
3. Discussion
Anticoagulant-related nephropathy (ARN) is a form of
acute kidney injury caused by excessive anticoagulation first
described with warfarin, and because of that it is called
Figure 2: Interstitial hemorrhage (Masson’s trichrome, magnifica-
tion 100x).
Figure 3: Direct immunofluorescence showing granular mesangial
staining for IgA in the expanded mesangium of the biopsy, magnifi-
cation 400x.
warfarin-related nephropathy (WRN) [1]. Diagnosis should
be suspected among patients who present with unexplained
acute renal injury defined as a serum creatinine increase
greater than 0.3mg/dL within one week of an INR mea-
surement greater than 3 in a patient treated with warfarin,
excluding other causes of AKI and bleeding [1, 2]. Recent evi-
dence suggests thatWRN-like syndromes are not confined to
anticoagulation with warfarin but may occur with other anti-
coagulants, such as acenocoumarol [3] and dabigatran [2].
In WRN AKI occurs through glomerular hematuria
with subsequent widespread tubular obstruction [4]. Biopsy
studies showed RBCs in tubules and occlusive RBCs casts
predominantly in distal nephron segments [4, 5]. Several
pathogenic mechanisms were proposed. The combination of
even mild glomerular disease and warfarin-induced coagu-
lopathy seems to be the key point [4].This leads to glomerular
hematuria and to a significant accumulation of RBCs within
nephrons that form occlusive casts, especially when urinary
flow is diminished [4, 6]. Although glomerular hematuria is
essential, it seems that interstitial hemorrhage may also have
an important role [3]. So the dominant mechanism of AKI in
WRN is probably tubular obstruction by RBC casts, which,
associated with interstitial hemorrhage, leads to increased
oxidative stress in the kidney [7, 8].
There are many underlying risk factors for WRN, such
as age, CKD, due to higher risk of supratherapeutic INR,
Case Reports in Nephrology 3
diabetes and diabetic nephropathy, hypertension, and heart
failure [5].
Dabigatran is an anticoagulant used for stroke preven-
tion in atrial fibrillation [9]. Recent evidence suggests that
dabigatran has many hemorrhagic complications. However,
in what concerns kidney involvement, information is scarce
[10]. Dabigatran has 80% renal elimination and is not rec-
ommended for patients with creatinine clearance less than
15mL/min or on dialysis, needing a dose adjustment in
patients with creatinine clearance between 15 and 30mL/min,
in order to reduce hemorrhagic complications [11].
Evidence from animal studies revealed that dabigatran
may cause AKI by two major pathogenic mechanisms: first,
tubular obstruction by RBCs and, second, a mechanism
possibly involving protease-activated receptor 1 (PAR-1) [1].
PAR-1 is a G protein-coupled receptor that participates in the
regulation of the endothelial functions, vascular permeability,
leukocytemigration, and adhesion and is themajor effector of
thrombin signaling [3]. Either vitaminK antagonists or direct
thrombin inhibitors decrease thrombin activity. By acting on
thrombomodulin, thrombin activates protein C and mod-
ulates the anticoagulation cascade. The same happens with
PAR-1. In the aforementioned study the authors proposed
that thrombin plays an important role in the glomerular
filtration barrier function, and its decreased activity (sec-
ondary to anticoagulation) results in glomerular filtration
barrier abnormalities. Indeed, treatment with selective PAR-
1 inhibitor results in increased creatinine, hematuria, and
tubular RBC casts, findings similar to those in animals with
WRN or treated with dabigatran. These effects are similar to
WRN.However in contrast toWRN,where kidney injurywas
seen only in animals with CKD, the effects of dabigatran were
prominent in control rats as well. These findings suggest that
the kidney risk with dabigatran may be greater than that of
warfarin [3].
To the best of our knowledge, only two cases of
dabigatran-induced AKI have been reported [12, 13]. In both
cases patients presented with hematuria and had histologic
evidence of hemorrhage into renal tubules. In the Moeckel
et al. clinical report the patient had previously mild undi-
agnosed IgA nephropathy [13], as presented in our case.
This raises the question if IgA nephropathy is a risk factor
or a predisposing condition in anticoagulated patients with
dabigatran as was described in WRN. The main clinical
feature of IgA nephropathy is hematuria, which can bemicro-
or macroscopic, both unnoticed by our patient, and it is
plausible to think that an entity, which, by nature, already pre-
disposes hematuria, may be related or may be a risk factor to
ARN. Fundamental WRN pathological lesions as described
above were also observed in our patient, which suggests that
the physiopathological mechanisms that induce AKI may
have a common way, particularly with regard to tubular
obstruction and interstitial hemorrhage. In our patient’s case
we propose that the combination of IgA nephropathy which
associated with the age, CKD, and the medical history of
hypertension possibly leads to the perfect background.
Concerning treatment, restoring the aPTT into a ther-
apeutic range while doing supportive renal treatment is
primordial [1]. In what concerns dabigatran-related AKI
hemodialysis seems to be effective [9, 13, 14]. About the
prognosis, there seem to be discrepancies between WRN
and dabigatran-related AKI. The clinical outcome in a WRN
study was unfavorable: 66% of patients did not recover
baseline function [4]. With regard to the two reported cases
of dabigatran-induced AKI, in both renal function improved
[12, 13]. In our case, there seems to be a recovery of renal
function and we think that the absence of histological mark-
ers of poor prognosis of IgA nephropathy, such as the lack of
interstitial fibrosis, tubular atrophy, glomerular sclerosis, or
endocapillary hypercellularity,may possibly have contributed
to this good outcome.The short period of administration and
the lower dose of dabigatran may also have had influence.
However, since there are so fewpublished cases of dabigatran-
related nephropathy, it is impossible to compare outcomes of
these two entities.
This raises the note of caution about oral anticoagulation
in patients with kidney disease. They are at a higher risk of
overanticoagulation, gross hematuria, andAKI [15]. So physi-
cians involved in the clinical management of anticoagulated
patients should be aware of the ARN, either by warfarin or
other anticoagulants like dabigatran. A correct coagulation
and kidney function monitoring is required and, if needed,
anticoagulants should be stopped or decreased [15].
Consent
The patient described in the case report had given informed
consent for the case report to be published.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
References
[1] M. Ryan, K.Ware, Z. Qamri et al., “Warfarin-related nephropa-
thy is the tip of the iceberg: direct thrombin inhibitor dabigatran
induces glomerular hemorrhage with acute kidney injury in
rats,” Nephrology Dialysis Transplantation, vol. 29, no. 12, pp.
2228–2234, 2014.
[2] D. V. Rizk and D. G. Warnock, “Warfarin-related nephropathy:
another newly recognized complication of an old drug,” Kidney
International, vol. 80, no. 2, pp. 131–133, 2011.
[3] C. M. Cleary, J. A. Moreno, B. Ferna´ndez et al., “Glomerular
haematuria, renal interstitial haemorrhage and acute kidney
injury,” Nephrology Dialysis Transplantation, vol. 25, no. 12, pp.
4103–4106, 2010.
[4] S. V. Brodsky, A. Satoskar, J. Chen et al., “Acute kidney injury
during warfarin therapy associated with obstructive tubular red
blood cell casts: a report of 9 cases,” The American Journal of
Kidney Diseases, vol. 54, no. 6, pp. 1121–1126, 2009.
[5] S. V. Brodsky, T. Nadasdy, B. H. Rovin et al., “Warfarin-related
nephropathy occurs in patients with and without chronic
kidney disease and is associated with an increased mortality
rate,” Kidney International, vol. 80, no. 2, pp. 181–189, 2011.
[6] D. Wheeler and J. Rangaswami, Anticoagulation-Related
Nephropathy: The Clot Thickens, 2014, http://www.acc.org/.
4 Case Reports in Nephrology
[7] K. Ware, Z. Qamri, A. Ozcan et al., “N-acetylcysteine amelio-
rates acute kidney injury but not glomerular hemorrhage in an
animal model of warfarin-related nephropathy,” The American
Journal of Physiology—Renal Physiology, vol. 304, no. 12, pp.
F1421–F1427, 2013.
[8] M. J. Tracz, J. Alam, and K. A. Nath, “Physiology and patho-
physiology of heme: implications for kidney disease,” Journal of
the American Society of Nephrology, vol. 18, no. 2, pp. 414–420,
2007.
[9] A.Majeed,H.-G.Hwang, S. J. Connolly et al., “Management and
outcomes of major bleeding during treatment with dabigatran
or warfarin,” Circulation, vol. 128, no. 21, pp. 2325–2332, 2013.
[10] G. J. Hankey and J. W. Eikelboom, “Dabigatran etexilate: a new
oral thrombin inhibitor,” Circulation, vol. 123, no. 13, pp. 1436–
1450, 2011.
[11] Z. Hijazi, S. H. Hohnloser, J. Oldgren et al., “Efficacy and
safety of dabigatran compared with warfarin in relation to
baseline renal function in patients with atrial fibrillation: a
RE-LY (randomized evaluation of long-term anticoagulation
therapy) trial analysis,” Circulation, vol. 129, no. 9, pp. 961–970,
2014.
[12] D. Kadiyala, U. C. Brewster, and G. W. Moeckel, “Dabigatran
induced acute kidney injury,” in Proceedings of the American
Society of Nephrology Annual Meeting, 2012.
[13] G. W. Moeckel, R. L. Luciano, and U. C. Brewster, “Warfarin-
related nephropathy in a patient with mild IgA nephropathy on
dabigatran and aspirin,”Clinical Kidney Journal, vol. 6, no. 5, pp.
507–509, 2013.
[14] F. Knauf, C. M. Chaknos, J. S. Berns, and M. A. Perazella,
“Dabigatran and kidney disease: a bad combination,” Clinical
Journal of the American Society of Nephrology, vol. 8, no. 9, pp.
1591–1597, 2013.
[15] C. Santos, A. M. Gomes, A. Ventura, C. Almeida, and J. Seabra,
“An unusual cause of glomerular hematuria and acute kidney
injury in a chronic kidney disease patient during warfarin
therapy,” Nefrologia, vol. 33, no. 3, pp. 400–403, 2013.



















































 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
